In this study, we developed a novel radiomic biomarker that integrates with PDL1 expression, ECOG status, BMI, and smoking status data to enhance the ability to predict progression-free survival in patients with stage 4 NSCLC, treated with first line PEMBRO monotherapy or combination therapy. Here, CD274 is linked to non-small cell lung carcinoma.